Drug Profile
Tipranavir
Alternative Names: Aptivus; Elodius; PNU 140690; TipranivirLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Boehringer Ingelheim
- Class Antivirals; Pyridines; Pyrones
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 28 Oct 2008 Drug interactions data of tipranavir co-administered with ritonavir and buprenorphine/naloxone and with valaciclovir presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008) ,
- 06 Aug 2008 Preregistration for HIV-1 infections (treatment-experienced paediatric, adolescent and adult patients) in the European Union (PO, solution)
- 06 Aug 2008 The 2-year follow-up efficacy data in paediatric patients with HIV-1 infections released by Boehringer-Ingelheim